Glucagon-like peptide-1 (GLP-1) is an endogenous peptide hormone whose metabolic effects have been exploited for glycaemic control in diabetes, but which also exerts important cardiovascular actions. We have recently reported that the GLP-1 mimetic, exendin-4, exerts clear benefits post-myocardial infarction via specific effects on extracellular matrix remodelling which is dysregulated in the diabetic heart (Robinson E et al, Basic Res Cardiol 2015; 110: 20), and have now shown similar cardioprotective actions in experimental diabetes, which are mediated via direct effects on infiltrating macrophages (Tate M et al, Basic Res Cardiol 2016; 111: 1). Taken together with the apparent complexity of GLP-1 signalling and disappointing results of recent cardiovascular trials, our work strongly suggests that selective targeting of GLP-1 may be required in order to realise therapeutic benefit for both diabetic and non-diabetic heart failure patients. This is particularly important given the epidemic increase in the incidence of diabetes which is associated with a markedly enhanced susceptibility to cardiovascular stress.
|Publication status||Accepted - 06 Feb 2016|
|Event||Scottish Cardiovascular Forum -Annual Conference - Wellcome-Wolfson Research Institute, Belfast, United Kingdom|
Duration: 06 Feb 2016 → 06 Feb 2016
|Conference||Scottish Cardiovascular Forum -Annual Conference|
|Period||06/02/2016 → 06/02/2016|
Grieve, D., Robinson, E., Tate, M., Green, B., & McDermott, B. (Accepted/In press). Glucagon-like peptide-1 based therapies as a novel approach for chronic heart failure. Abstract from Scottish Cardiovascular Forum -Annual Conference, Belfast, United Kingdom. http://www.scf.strath.ac.uk/